Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2019 07:00 ET | Source: AC Immune SA

New Clinical Data on AC Immune’s Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD™ Conference

Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSP New data further support 18F-PI-2620’s potential as a new PET Tracer for...
March 21, 2019 07:00 ET | Source: AC Immune SA

AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update

CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023Eli Lilly deal validates MorphomerTM platformInitiation of second Phase 2 trial of Tau antibody by partner...
March 21, 2019 07:00 ET | Source: AC Immune SA

AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update

CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates MorphomerTM platform Initiation of second Phase 2 trial of Tau antibody by partner Genentech ...
March 04, 2019 10:28 ET | Source: AC Immune SA

AC Immune to Report Progress of Early-Stage Pipeline at AD/PD[TM] Congress

Lausanne, Switzerland, March 4, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
March 04, 2019 09:59 ET | Source: AC Immune SA

AC Immune to Report Progress of Early-Stage Pipeline at AD/PD™ Congress

LAUSANNE, Switzerland, March 04, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
February 20, 2019 07:00 ET | Source: AC Immune SA

AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease

Study complements ongoing trial in the prodromal to mild population LAUSANNE, Switzerland, Feb. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage...
February 07, 2019 07:00 ET | Source: AC Immune SA

AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development

LAUSANNE, Switzerland, Feb. 07, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
January 30, 2019 01:00 ET | Source: AC Immune SA

AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease

Decision follows Independent Data Monitoring Committee analysisThe Alzheimer’s Prevention Initiative (API) study of crenezumab in familial Alzheimer’s disease continuesThe Phase II anti-tau TAURIEL...
January 03, 2019 04:00 ET | Source: AC Immune SA

AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer

Lausanne, Switzerland, January 3, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on Neurodegenerative Diseases, today...
December 19, 2018 06:30 ET | Source: AC Immune SA

AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership

AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Entities against CNS disorders including proprietary WuXiUP continuous manufacturing platform that can...